Ependymoma

Researchers are testing a radioactive gel called rhenium-186 obisbemeda in children and young adults, ages 6 to 21, whose ependymoma or high-grade glioma has come back or keeps growing after treatment. The gel is infused directly into the tumor through a thin tube, a method calle…

This study tests a combination of drugs given in low, frequent doses to slow or stop the growth of recurrent brain tumors in children. The goal is to extend survival while maintaining quality of life. About 232 children with medulloblastoma, ependymoma, ATRT, or other rare CNS tu…

This early-stage trial tests whether using focused ultrasound with microbubbles can temporarily open the blood-brain barrier, allowing the immunotherapy drug nivolumab to reach brain tumors more effectively. It includes 30 children and young adults with relapsed diffuse midline g…

This early-stage trial tests whether a specially engineered herpes virus (G207) is safe to inject directly into the brain tumors of children whose cancer has returned. Up to 24 children aged 3 to 21 will receive the virus, and some will also get a small dose of radiation to help …

This early-phase study tests the safety of a new cell therapy called B7-H3 CAR T cells for children and young adults whose brain tumors have come back or are growing despite standard treatment. The therapy uses the patient's own immune cells, modified to target a protein (B7-H3) …

This study tests several experimental drugs in people with NF2-related schwannomatosis, a genetic condition that causes non-cancerous tumors on nerves. The goal is to see if these drugs can shrink tumors and control the disease. About 109 participants will receive one of three dr…

This study tests a drug called PLX038 in adults with brain or spinal cord tumors, including those with changes in the MYC or MYCN genes. The trial has two phases: first, finding the right dose, then checking if it works. Participants receive PLX038 intravenously every three weeks…

This study is testing a drug called Lutathera in children and young adults (ages 4 to 39) whose brain tumors have come back or are growing despite treatment. The drug delivers radiation directly to tumor cells that show up on a special PET scan. The goal is to find the safest dos…

This phase 1 trial tests a drug called 177Lu-DTPA-omburtamab, which delivers radiation directly to tumor cells in children and teens with recurrent or refractory medulloblastoma or other central nervous system (CNS) tumors that have spread. The drug targets a protein called B7-H3…

This early-stage trial tests whether personalized immune cells (T-cells) can safely treat young children with aggressive brain tumors. The T-cells are designed to attack unique markers found on each child's tumor. Up to 12 children under 5 with embryonal brain tumors or recurrent…

This early-phase trial tests a new drug called ONC206 in children and young adults with diffuse midline glioma or other recurrent brain tumors. The drug aims to kill cancer cells by causing stress in them, without harming healthy cells. Researchers are looking for the safest dose…

This study is testing a combination of two drugs—a targeted radioactive drug (177Lu-DOTATATE) and a PARP inhibitor (olaparib)—in children and teens aged 3 to 18 with certain solid tumors that have come back or not responded to treatment. The goal is to see if the combination is s…

This phase 2 trial tests whether a single injection of DNX-2401, a virus designed to kill cancer cells, can shrink or stabilize recurrent high-grade brain tumors in 39 children and young adults. Participants receive the virus directly into the tumor during a biopsy procedure. The…

This early-stage trial tests a precise type of proton radiation for children with ependymoma, a brain tumor. The therapy is designed to kill cancer cells while reducing damage to healthy brain tissue. About 48 children will take part to see if the treatment is safe and what side …

This early-stage trial tests whether a device called SonoCloud-9 can safely open the blood-brain barrier in children aged 5 to 17 with recurrent malignant brain tumors. The barrier normally blocks chemotherapy from reaching the brain. By using low-intensity ultrasound just before…

This early-phase trial is testing a combination of three treatments for children whose brain tumors have come back or not responded to standard care. The experimental drug SGT-53 delivers a normal TP53 gene to tumor cells, and is given alongside the immunotherapy Nivolumab and ra…

This early-phase study tests whether a new type of immunotherapy, called B7-H3 CAR T cells, can be safely given directly into the brain or spinal fluid of children and young adults with aggressive brain tumors like DIPG, DMG, or other recurrent central nervous system cancers. The…

This early-phase trial is testing whether adding the drug ibrutinib to a chemo-immunotherapy regimen can safely help children and young adults (ages 6–25) with brain cancers that have come back or not responded to standard treatment. The study combines ibrutinib with indoximod an…

This early-stage study tests an oral drug called ONC206 in adults with brain tumors that have come back. The main goal is to find the safest dose and check for side effects. About 102 participants will take the drug once or several times a week.

This phase 3 trial compares proton beam therapy to standard photon radiotherapy in 156 adults with primary brain tumors. The goal is to see if proton therapy, which delivers less radiation to healthy brain tissue, improves functional survival—meaning living longer without tumor r…

This study is testing whether a special MRI technique called magnetic resonance elastography (MRE) can measure how stiff a spinal cord tumor is and how strongly it sticks to surrounding tissue before surgery. Knowing this could help surgeons choose the best approach and make oper…

This Phase 3 trial tests whether metformin, a widely used diabetes drug, can improve memory and thinking in children and teens who have finished treatment for a brain tumor. About 140 participants aged 7 to 21 will take metformin or a placebo for 16 weeks. Researchers will measur…

This study tests a lab technique called pharmacoscopy that analyzes a patient's tumor tissue to find which drugs might work best for them. It includes 40 adults with various aggressive or rare brain tumors that have not responded to standard treatments. The main goal is to see if…

This study follows 269 people with neurofibromatosis type 2 (NF2) for up to 10 years to learn how the disease progresses. Participants will have yearly exams, MRI scans, hearing tests, and blood draws. The goal is to understand tumor growth, hearing loss, and speech or swallowing…

This study is testing a new approach for children and young adults whose medulloblastoma or ependymoma has come back. Researchers will analyze each person's tumor using drug screening and genetic testing to create a personalized treatment plan. The goal is to find the most effect…

This study looks at how radiation to the brain affects memory in children who had a brain tumor. Researchers will test memory and thinking skills in 130 children ages 4 to 12, starting 2 years after radiation and again 2 years later. The goal is to learn which parts of the brain …

This study is collecting data from 1,650 people with various brain tumors to see if the updated 2021 WHO classification system helps doctors group patients more accurately and choose better treatments. Researchers will track responses to therapy, survival, and tumor features over…

This international registry collects medical data and biological samples from children and adults with rare brain tumors like medulloblastoma and ependymoma. By gathering information from patients not in clinical trials, researchers hope to improve treatment recommendations and i…